Olesoxime accelerates myelination and promotes repair in models of demyelination
Authors:
- Joseph KhaldiJKJoseph Khaldi
- Clarisse BourbonCBClarisse Bourbon
- Isabelle RoblesIRIsabelle Robles
- Gwenaëlle TardifGTGwenaëlle Tardif
- Thierry BordetThierry Bordet
- Pascale DurbecPDPascale Durbec
- 17 August 2011
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 71 (2) , 213-226
Abstract
Objective: Multiple sclerosis is a neurodegenerative disease characterized by episodes of immune attack of oligodendrocytes leading to demyelination and progressive functional deficit. One therapeutic strategy to address disease progression could consist in stimulating the spontaneous regenerative process observed in some patients. Myelin regeneration requires endogenous oligodendrocyte progenitor migration and activation of the myelination program at the lesion site. In this study, we have tested the ability of olesoxime, a neuroprotective and neuroregenerative agent, to promote remyelination in the rodent central nervous system in vivo.Methods: The effect of olesoxime on oligodendrocyte progenitor cell (OPC) differentiation and myelin synthesis was tested directly in organotypic slice cultures and OPC–neuron cocultures. Using naive animals and different mouse models of demyelination, we morphologically and functionally assessed the effect of the compound on myelination in vivo.Results: Olesoxime accelerated oligodendrocyte maturation and enhanced myelination in vitro and in vivo in naive animals during development and also in the adult brain without affecting oligodendrocyte survival or proliferation. In mouse models of demyelination and remyelination, olesoxime favored the repair process, promoting myelin formation with consequent functional improvement.Interpretation: Our observations support the strategy of promoting oligodendrocyte maturation and myelin synthesis to enhance myelin repair and functional recovery. We also provide proof of concept that olesoxime could be useful for the treatment of demyelinating diseases. ANN NEUROL 2012;71:213–226Keywords
This publication has 45 references indexed in Scilit:
- Interactions between oligodendrocyte precursors control the onset of CNS myelinationDevelopmental Biology, 2011
- Oestrogen receptor β ligand: a novel treatment to enhance endogenous functional remyelinationBrain, 2010
- Axon‐oligodendrocyte interactions during developmental myelination, demyelination and repairJournal of Neurochemistry, 2010
- Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective CompoundPharmaceuticals, 2010
- Tubulin polymerization‐promoting protein (TPPP/p25) is critical for oligodendrocyte differentiationGlia, 2009
- Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis?Brain, 2007
- Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosisProceedings of the National Academy of Sciences, 2007
- Insulin‐like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelinationGlia, 2006
- Secondary progressive multiple sclerosis: current knowledge and future challengesThe Lancet Neurology, 2006
- Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in miceJournal of Neurocytology, 1972